Dec 20 (Reuters) - Stealth BioTherapeutics Corp said on Friday its drug to treat neuromuscular diseases failed to meet the main goals of a late-stage trial.
The trial was testing the drug, elamipretide, to treat patients with primary mitochondrial myopathy, but failed to help patients walk better and reduce fatigue, the company said. (reut.rs/3918ob9) (Reporting by Trisha Roy in Bengaluru; Editing by Shounak Dasgupta)
Our Standards: The Thomson Reuters Trust Principles.